Louisiana State Employees Retirement System raised its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report) by 14.0% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 70,900 shares of the biotechnology company’s stock after acquiring an additional 8,700 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Ironwood Pharmaceuticals were worth $754,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. boosted its stake in Ironwood Pharmaceuticals by 1.2% during the 1st quarter. BlackRock Inc. now owns 14,536,759 shares of the biotechnology company’s stock valued at $182,873,000 after purchasing an additional 167,869 shares during the last quarter. State Street Corp lifted its position in Ironwood Pharmaceuticals by 5.2% during the third quarter. State Street Corp now owns 11,454,170 shares of the biotechnology company’s stock valued at $118,665,000 after purchasing an additional 567,365 shares during the period. Renaissance Technologies LLC lifted its position in Ironwood Pharmaceuticals by 6.0% during the first quarter. Renaissance Technologies LLC now owns 4,637,753 shares of the biotechnology company’s stock valued at $48,789,000 after purchasing an additional 263,600 shares during the period. Dimensional Fund Advisors LP lifted its position in Ironwood Pharmaceuticals by 25.8% during the first quarter. Dimensional Fund Advisors LP now owns 4,609,079 shares of the biotechnology company’s stock valued at $48,487,000 after purchasing an additional 946,481 shares during the period. Finally, Millennium Management LLC lifted its position in Ironwood Pharmaceuticals by 121.0% during the fourth quarter. Millennium Management LLC now owns 3,989,942 shares of the biotechnology company’s stock valued at $49,435,000 after purchasing an additional 2,184,767 shares during the period.
Insider Buying and Selling at Ironwood Pharmaceuticals
In related news, CFO Sravan Kumar Emany purchased 36,072 shares of the business’s stock in a transaction on Friday, September 15th. The stock was acquired at an average price of $8.32 per share, with a total value of $300,119.04. Following the completion of the acquisition, the chief financial officer now owns 188,730 shares of the company’s stock, valued at approximately $1,570,233.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 13.10% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
View Our Latest Research Report on IRWD
Ironwood Pharmaceuticals Stock Down 0.3 %
NASDAQ IRWD opened at $9.59 on Tuesday. Ironwood Pharmaceuticals, Inc. has a 52 week low of $8.07 and a 52 week high of $12.66. The firm has a market capitalization of $1.50 billion, a P/E ratio of -1.59 and a beta of 0.91. The company has a 50-day moving average price of $9.48 and a 200-day moving average price of $10.26.
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.06. Ironwood Pharmaceuticals had a positive return on equity of 55.17% and a negative net margin of 214.68%. The business had revenue of $107.38 million during the quarter, compared to analyst estimates of $103.46 million. As a group, equities research analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 1.28 EPS for the current year.
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries.
Featured Stories
- Five stocks we like better than Ironwood Pharmaceuticals
- How to Invest in Blockchain Stocks Step by Step
- MarketBeat ‘Stock of the Week’ Ford, Strike Presents Opportunity
- Investing in Blue-Chip Stocks
- Healthcare Giant Outperforms: A Healthy Dose of Market Resilience
- What is Short Interest? How to Use It
- 5 Reasons Rivian is a Buy on Shaken Investor Sentiment
Want to see what other hedge funds are holding IRWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Free Report).
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
